New Articles

These are the latest Alerts we've found that meet your personalized settings.

No alerts showing?
- You may not have selected a clinical discipline(s) yet; go to Personalized Alert Settings to do that.
- If you have just updated your profile with a newly selected clinical discipline(s), you will begin to receive alerts as soon as we find articles that fit your interests. Meanwhile, please feel free to Search the database for articles of interest or review Featured Article.
- You may have recently deleted your alerts and more will come according to the schedule you indicated when you registered.
If you would like to change the number or types of alerts, please change your personalized settings at Alert Setup.
All alerts are also in the EvidenceUpdates database; please find them by going to Search.

< Previous

Next >

Wuhl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009 Oct 22;361(17):1639-50. (Original) PMID: 19846849
Read Abstract Read Comments
Clinical Evidence Topic: Chronic Renal Failure
DISCIPLINE	RELEVANCE TO PRACTICE	IS THIS NEWS?
Nephrology
Pediatrics (General)

Save Article Delete Article Email this article to a colleague Printer Friendly Version

Abstract
BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor. METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion. RESULTS: A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan-Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P=0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease. CONCLUSIONS: Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.)

Abstract

BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting-enzyme (ACE) inhibitor.
METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m(2) of body-surface area) received ramipril at a dose of 6 mg per square meter of body-surface area per day. Patients were randomly assigned to intensified blood-pressure control (with a target 24-hour mean arterial pressure below the 50th percentile) or conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile), achieved by the addition of antihypertensive therapy that does not target the renin-angiotensin system; patients were followed for 5 years. The primary end point was the time to a decline of 50% in the glomerular filtration rate or progression to end-stage renal disease. Secondary end points included changes in blood pressure, glomerular filtration rate, and urinary protein excretion.
RESULTS: A total of 29.9% of the patients in the group that received intensified blood-pressure control reached the primary end point, as assessed by means of a Kaplan-Meier analysis, as compared with 41.7% in the group that received conventional blood-pressure control (hazard ratio, 0.65; confidence interval, 0.44 to 0.94; P=0.02). The two groups did not differ significantly with respect to the type or incidence of adverse events or the cumulative rates of withdrawal from the study (28.0% vs. 26.5%). Proteinuria gradually rebounded during ongoing ACE inhibition after an initial 50% decrease, despite persistently good blood-pressure control. Achievement of blood-pressure targets and a decrease in proteinuria were significant independent predictors of delayed progression of renal disease.
CONCLUSIONS: Intensified blood-pressure control, with target 24-hour blood-pressure levels in the low range of normal, confers a substantial benefit with respect to renal function among children with chronic kidney disease. Reappearance of proteinuria after initial successful pharmacologic blood-pressure control is common among children who are receiving long-term ACE inhibition. (ClinicalTrials.gov number, NCT00221845.)

Comments from Clinical Raters
Nephrology This article serves as evidence-based information to pediatric nephrologists who already had some information about the benefits of strict blood pressure control and deceleration in progressing to ESRD in adults. The same mechanisms may be operative in children also. However, I do not think the strict blood pressure control is as easy in children as it is in adults.
Nephrology The most relevant finding in this report is that beneficial renoprotect effect of ACE blockade in patients congenital hypo/dysplastic kidney is, probably, confirmed.
Nephrology Excellent study in the area of pediatric hypertension in chronic renal disease.
Pediatrics (General) This is a thorough European study worthy of 11 pages in NEJM; therefore, relevant,important and scientifically rigorous. The information that tight BP control is helpful in CRF is not new, but this study copper-fastens this practice in children. Good BP control delays progression of CRF, whether it be due to infantile polycystic kidneys, FSGS, or whatever. Children with CRF need to have their BP measured, monitored and reduced to age-related norms. Paediatrics needs more high quality pharmaceutical studies similar to this. The Heidelberg group deserve congrats.
Pediatrics (General) Of primary interest to pediatric nephrologists but interesting.

New Articles

Quick Search: